Quick Answer
LENZ Therapeutics, Inc. reported Earnings Per Share Diluted of $2.85 (loss) per share for the year ending 2025.
- LENZ Therapeutics, Inc. showed a decrease of -21.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from LENZ Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $3.45 (loss) per share | Q3 2021: $0.28 (loss) per share | Q1 2022: $0.48 (loss) per share | Q2 2022: $0.48 (loss) per share | Q3 2022: $0.45 (loss) per share | Q1 2023: $6.50 (loss) per share | Q2 2023: $7.53 (loss) per share | Q3 2023: $9.62 (loss) per share | Q1 2024: $3.53 (loss) per share | Q2 2024: $0.40 (loss) per share | Q3 2024: $0.38 (loss) per share | Q1 2025: $0.53 (loss) per share | Q2 2025: $0.53 (loss) per share | Q3 2025: $0.59 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), LENZ Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 16.3%.
- Historical annual values: Fiscal year 2025: $2.85 (loss) per share | Fiscal year 2024: $2.34 (loss) per share | Fiscal year 2023: $35.71 (loss) per share | Fiscal year 2022: $1.84 (loss) per share | Fiscal year 2021: $2.45 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: